TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Service Use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in carotid artery plaque volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative rate of cervical intraepithelial neoplasia 3 (CIN3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Level of immune response markers as prediction of long-term success of HPV vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in the rate of cervical lesions associated with other carcinogenic HPV types
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in NT-proBNP peri-operatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in mania symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative complication
Endpoint domain: Adverse events/effects
Primary endpoint: Left Ventricular dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical failure
Endpoint domain: Adverse events/effects
Primary endpoint: Mobility of the trapezometacarpal joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Compliance with taking prescribed medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area under the plasma drug concentration-time curve over 24 hours (AUC0-24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of second primary malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence rates of skeletal-related events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in ocular inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thromboembolic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Deviation from target score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to treatment initiation
Endpoint domain: Mortality/survival
Primary endpoint: time to health related quality of life score deterioration
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: time to health related quality of life score deterioration
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: time to health related quality of life score deterioration
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning
Primary endpoint: Proportion of subjects free from major adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Depth of penetration of nano particles in skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Recommended Ph2 dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of SAEs and AEs resulting in study discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Six-Minute Walk Test (6-MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With at Least One Unexplained Hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Patients With Confirmed Infusion Set Occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ipsilateral Invasive Breast Cancer Recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Ipsilateral Skin Cancer Recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Ipsilateral DCIS-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Mood and Feelings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: In-segment late lumen loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pathology regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of pain on harvesting of skin at donor site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to healing of donor sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rituximab C Trough Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of exploitable films
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change scores of Fugl-Meyer Assessment (FMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change scores of Motor Activity Log (MAL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change scores of Stroke Impact Scale Version 3.0 (SIS 3.0)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change scores of Revised Nottingham Sensory Assessment (rNSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angle of deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lesion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in irritable bowel severity score (IBSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of change in wound area of diabetic foot ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: clinical and laboratory safety
Endpoint domain: Adverse events/effects
Primary endpoint: Time to resolution of prolonged postoperative ileus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Active elbow joint position error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Composition Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change in energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: intense neuralgic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Anxiety levels measured by Likert scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to Withdrawal From Study
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Presence of genetic markers for local recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Score of System Usability Scale (SUS) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Behavioural intention
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Diabetes Symptomatology
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Multifidus cross sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: responder rate on SGRQ questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pressure Pain Threshold (Trigger Point)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pressure Pain Threshold (Patellar Tendon)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time limit for consultation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Significant number of PR or higher (>40%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of post-operative cervical esophagogastric anastomotic leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of manufacturing products not meeting release criteria
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: steady-state pharmacokinetic parameters of cediranib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with anti-brontictuzumab antibodies
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of methemoglobinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Surgically related readmissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change From Baseline in Body Weight at Week 12 - Stage A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Body Weight at Week 12 - Stage B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Body Weight at Week 12 - Stage C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Haemodynamic effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Receipt of Dental Care (restoration or extraction of at least one tooth)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Quantification of post-translational modification derived-products (PTMDP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for Ibandronate Monthly Dosing over Risedronate Weekly Dosing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: pharmacodynamic effect of HM15211
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of OABSS questionnaire and Urodynamic study
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injection of desired volume of rhBMP-2/CPM within the osteotomy defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ability to perform longitudinal radiographic absorptiometry of the defect in the presence of rhBMP-2/CPM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: classification of disability for Leprosy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New Mobility Score (NMS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overall Recruitment Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Treatment Attendance in the SSE Group
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Home Exercise Adherence in the SSE Group According to Weekly E-mails
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cardiac Troponin I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Any Potential Adverse Allergic Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: clinical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Without any Red Blood Cell (RBC) Transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: long term performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: HiMAT (High Mobility Assessment Tool)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limits of Stability instrumented balance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Depression (HAM-D) inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Caregiver's experience during COVID-19
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Family's overall experience with COVID-19 pandemic
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: The impact of school closure on the child
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in Hb level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cardiopulmonary test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity and Specificity of lung cancer diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Follicle number per ovary
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Treatment Participation Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of subjects with at least 50% improvement in hemangioma extent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of Participants Reporting Dose-Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: First episode of variceal bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Liver steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver and biliary outcomes
Primary endpoint: Average Pain Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of specific grade 3+ cardiopulmonary adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Best deepness of response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSA rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Chronic GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical success of socket shield technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinical success of SECT graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Specificity of the Multi-target Stool DNA Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Screen media use/viewing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Emergency Ultrasonography findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk for developing infection
Endpoint domain: Adverse events/effects
Primary endpoint: Risk for developing lymphoma
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Maximal aerobic capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Maximal voluntary contraction of knee extensors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Predicted Forced Expiratory Volume in 1 Second (FEV1 %Pred)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Predicted Total Diffusing Capacity of the Lungs for Carbon Monoxide (TLCO %Pred)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Modified Medical Research Council (MMRC) Dyspnoea Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percent Specificity of the Cytosponge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Sensitivity of the Cytosponge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gluten-free diet compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycemic Control (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Stroke (ischemic and hemorrhagic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Systemic embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pediatric Anxiety Rating Scale (PARS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical Global Improvement (CGI) Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Aggregated Mean Number of Nocturnal Voids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in Visual Analogue Scale of subjective Pelvic Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child's linear growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child's height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child's weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child's nutritional status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plaque location and activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in adherence rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Atrial fibrillation recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Low Frequency Power Spectral Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Clearance of All Treatable MC at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quick Disabilities of the Arm, Shoulder and Hand Score (Quick-DASH)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time of maximum plasma concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half life (t1/2) in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergency room (ER) visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Relative reduction in wound surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incremental area under the curve for blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incremental area under the curve for plasma insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Place of death of deceased patients
Endpoint domain: Mortality/survival
Primary endpoint: Time spent at home the last three months of the deceased patients lives
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Numbers of hospital admission the last three months of the deceased patients lives
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Methamphetamine-induced Mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Subjective Effects of Methamphetamine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Methamphetamine-induced Stimulation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: compliance with diabetes care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Final/ultimate success rate of an intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cohen-Mansfield Agitation Inventory (CMAI) Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease control at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Brown Adipose Tissue Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Peripheral Insulin Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Insulin Secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of grating acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dyspnea VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: unscheduled hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Reductions in cocaine use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of adenomatous colonic polyps > 6mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Anti HLA Immunization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Preservation of endothelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CNS tumor evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Weighed Food Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24-hour Dietary Recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes